Ligand Pharmaceuticals Incorporated (LGND) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $291.69 (-1.52%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Joseph Pantginis | H.C. Wainwright | $243.00 | -16.7% |
| Feb 24, 2026 | Joseph Pantginis | H.C. Wainwright | $239.00 | -18.1% |
| Dec 10, 2025 | Trevor Allred | Oppenheimer | $275.00 | -5.7% |
| Nov 6, 2025 | Annabel Samimy | Stifel Nicolaus | $220.00 | -24.6% |
| Nov 3, 2025 | Leland Gershell | Oppenheimer | $250.00 | -14.3% |
| Sep 3, 2025 | Leland Gershell | Oppenheimer | $190.00 | -34.9% |
| Oct 21, 2024 | Joseph Pantginis | H.C. Wainwright | $157.00 | -46.2% |
| Oct 2, 2024 | Leland Gershell | Oppenheimer | $135.00 | -53.7% |
| Jul 30, 2024 | Douglas Miehm | RBC Capital | $130.00 | -55.4% |
| Jul 9, 2024 | Matt Hewitt | Craig-Hallum | $140.00 | -52.0% |
| Jun 28, 2024 | Joseph Pantginis | H.C. Wainwright | $144.00 | -50.6% |
Top Analysts Covering LGND
LGND vs Sector & Market
| Metric | LGND | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 11 | 8 | 19 |
| Target Upside | +8.9% | +16366.1% | +18.0% |
| P/E Ratio | 39.58 | 2.97 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $68M | $70M | $72M | 4 |
| 2026-12-31 | $71M | $73M | $75M | 5 |
| 2027-12-31 | $307M | $318M | $341M | 7 |
| 2028-12-31 | $364M | $371M | $378M | 4 |
| 2029-12-31 | $403M | $422M | $447M | 3 |
| 2030-12-31 | $483M | $506M | $536M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $2.23 | $2.32 | $2.40 | 1 |
| 2026-12-31 | $2.34 | $2.44 | $2.53 | 1 |
| 2027-12-31 | $9.33 | $9.93 | $10.34 | 6 |
| 2028-12-31 | $4.42 | $10.30 | $20.78 | 3 |
| 2029-12-31 | $10.57 | $11.25 | $12.10 | 1 |
| 2030-12-31 | $13.63 | $14.51 | $15.60 | 1 |
Frequently Asked Questions
What is the analyst consensus for LGND?
The consensus among 11 analysts covering Ligand Pharmaceuticals Incorporated (LGND) is Buy with an average price target of $291.00.
What is the highest price target for LGND?
The highest price target for LGND is $275.00, set by Trevor Allred at Oppenheimer on 2025-12-10.
What is the lowest price target for LGND?
The lowest price target for LGND is $130.00, set by Douglas Miehm at RBC Capital on 2024-07-30.
How many analysts cover LGND?
11 analysts have issued ratings for Ligand Pharmaceuticals Incorporated in the past 12 months.
Is LGND a buy or sell right now?
Based on 11 analyst ratings, LGND has a consensus rating of Buy (2.00/5) with a +8.9% upside to the consensus target of $291.00.
What are the earnings estimates for LGND?
Analysts estimate LGND will report EPS of $2.32 for the period ending 2026-09-30, with revenue estimated at $70M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.